Report from Annual General Meeting in SyntheticMR AB 2018
The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on April 25, 2018, whereby the meeting resolved in accordance with the Board's proposed resolutions. The full resolutions are stated in the notice of the meeting.
During his presentation at the Annual General Meeting, CEO Stefan Tell talked about, among other things, developments in 2017 and the first quarter of 2018.
"2017 was another year of strong growth and further development of our partnerships. Sales of MAGiC via GE Healthcare developed well and important steps were taken to make MAGiC functionality available in the reading room. Also, an additional agreement was signed with Siemens, which meant that SyMRI will be available through syngo.via Open apps, that are now being launched in Q2 2018. A trend noted in 2017 was that the number of independent studies increased. This is a good indication that SyMRI gains a stronger footing on the market, "says Stefan Tell.
"The first quarter was characterized by continued sales growth and important regulatory clearances. We have received clearance for SyMRI NEURO from the FDA, which means that our entire product package can now be offered to hospitals and clinics in the US market. In addition to this, GE Healthcare has received clearance for MAGiC in China from China Food and Drug Administration (CFDA). Furthermore, the Philips sequence that allows the use of SyMRI has been cleared by the FDA. These approvals are an important part of our continued establishment of SyMRI in markets around the world, "continues Tell.
The following resolutions were made at the AGM:
The AGM resolved that the profit for the year, 8 361 054: - is carried forward. Remaining share premium reserve, 17,761,503: - and retained earnings, 1,105,508: -, total 27,228,065: - is carried forward.
The AGM resolved to grant the Board of directors and CEO discharge.
The AGM decided that the Board should consist of 4 ordinary members and no deputies. The re-election of the Board members, Jan Bertus Marten Warntjes, Johan Sedihn, Yvonne Mårtensson and Staffan Persson. Staffan Persson is re-elected Chairman of the Board.
For further information, please contact Fredrik Jeppsson, CFO and Head of Investor Relations SyntheticMR AB, +46 72 303 13 39 or Stefan Tell, CEO SyntheticMR AB, +46 73 373 40 90.
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple, adjustable contrast images and quantitative data from a single 5-6-minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com